ADIL Adial Pharmaceuticals Inc

1.38
+0.08  (+6%)
Previous Close 1.3
Open 1.29
Price To Book 2.03
Market Cap 14,461,852
Shares 10,479,603
Volume 81,162
Short Ratio
Av. Daily Volume 72,431
Stock charts supplied by TradingView

NewsSee all news

  1. Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today

  2. Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19

    CHARLOTTESVILLE, VA / ACCESSWIRE / March 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  3. Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria

    CHARLOTTESVILLE, VA / ACCESSWIRE / February 19, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  4. Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat

    CHARLOTTESVILLE, VA / ACCESSWIRE / February 14, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, is pleased to

  5. Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

    CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 initiation announced February 6, 2020 with data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023.
AD04
Alcohol use disorder

Latest News

  1. Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today

  2. Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19

    CHARLOTTESVILLE, VA / ACCESSWIRE / March 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  3. Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria

    CHARLOTTESVILLE, VA / ACCESSWIRE / February 19, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  4. Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat

    CHARLOTTESVILLE, VA / ACCESSWIRE / February 14, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, is pleased to

  5. Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

    CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  6. Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries

    CHARLOTTESVILLE, VA / ACCESSWIRE / December 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  7. Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

    CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  8. Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial

    Reports regulatory progress in Europe and imminent commencement of clinical trial CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL, ADILW)), a

  9. Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for

  10. Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided

  11. Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today

  12. Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    Application for pediatric investigation plan waiver validated by European Medicines Agency CHARLOTTESVILLE, VA / ACCESSWIRE / September 5, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage